Literature DB >> 11311926

Effect of medroxyprogesterone pretreatment on pentagastrin-induced panic symptoms in females with panic disorder.

J Le Mellédo1, G S Jhangri, P Lott, G R Tait, K McManus, M Geddes, W Chrapko, N Lara.   

Abstract

Clinical observation, as well as epidemiological and research data, suggest that female gonadal hormones influence the course of panic disorder (PD). Panicogenic agents such as pentagastrin are useful tools with which to study the pathophysiology of panic attacks. Nine women with PD were randomly assigned to receive, in a crossover design, a 3-day pretreatment with medroxyprogesterone acetate (MP) prior to an injection of pentagastrin, and a 3-day pretreatment with a placebo prior to another injection of pentagastrin. The panic response and the anxiety response to pentagastrin were decreased after MP pretreatment. These preliminary results support the use of laboratory models for investigations of the interactions between progestins and anxiety.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311926     DOI: 10.1016/s0165-1781(01)00233-5

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

Review 1.  Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders.

Authors:  Anna-Carin N-Wihlbäck; Inger Sundström-Poromaa; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2005-12-15       Impact factor: 4.530

2.  Progesterone turnover to its 5α-reduced metabolites in the ventral tegmental area of the midbrain is essential for initiating social and affective behavior and progesterone metabolism in female rats.

Authors:  C A Frye; J J Paris
Journal:  J Endocrinol Invest       Date:  2010-11-08       Impact factor: 4.256

Review 3.  Sex differences in progestogen- and androgen-derived neurosteroids in vulnerability to alcohol and stress-related disorders.

Authors:  MacKenzie R Peltier; Terril L Verplaetse; Yann S Mineur; Ralitza Gueorguieva; Ismene Petrakis; Kelly P Cosgrove; Marina R Picciotto; Sherry A McKee
Journal:  Neuropharmacology       Date:  2021-02-16       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.